Electroporation-Mediated siRNA Delivery into Tumors

  • Yoshifumi Takei
Part of the Methods in Molecular Biology book series (MIMB, volume 1121)


Electroporation-mediated gene transfer (electro-transfection) is a powerful tool to introduce nucleic acid compounds such as plasmid DNAs, antisense oligonucleotides, and short interfering RNAs (siRNAs) into the cells. Electro-transfection is a physical gene transfer method that utilizes an electrostatic field generated with an electroporator apparatus. Here, we demonstrate a practical protocol for electro-transfection (electro-delivery) of siRNA into cells in vivo and further demonstrate the application of the method to cancer therapy. We successfully developed an original electrode (the plate and fork-type electrode) and used it for in vivo electro-delivery of siRNA. Vascular endothelial growth factor (VEGF), an angiogenic factor, was chosen as a model target gene. Electro-delivery of an siRNA targeting VEGF into the xenografted tumors in nude mice significantly suppressed the growth of tumors. By repeating the therapy with a chemically modified siRNA after an interval of 20 days, satisfactory anticancer effects were achieved.

Key words

Electroporation Short interfering RNA (siRNA) Cancer therapy Vascular endothelial growth factor (VEGF) Prostate cancer 


  1. 1.
    Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotideRNAs mediate interference in cultured mammalian cells. Nature 411:494–498PubMedCrossRefGoogle Scholar
  2. 2.
    Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811PubMedCrossRefGoogle Scholar
  3. 3.
    Carpenter AE, Sabatini DM (2004) Systematic genome-wide screens of gene function. Nat Rev Genet 5:11–22PubMedCrossRefGoogle Scholar
  4. 4.
    Zheng L, Liu J, Batalov S et al (2004) An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci USA 101:135–140PubMedCrossRefGoogle Scholar
  5. 5.
    Karagiannis TC, El-Osta A (2004) Mechanism of RNA interference, in vivo and potential clinical applications. Cancer Biol Ther 3:1069–1074PubMedCrossRefGoogle Scholar
  6. 6.
    Ryther RCC, Flynt AS, Phillips JA III, Patton JG (2005) siRNA therapeutics: big potential from small RNAs. Gene Ther 12:5–11PubMedCrossRefGoogle Scholar
  7. 7.
    Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T (2004) A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 64:3365–3370PubMedCrossRefGoogle Scholar
  8. 8.
    Folkman J (1971) Tumor angiogenesis: therapeutic implications. New Engl J Med 285:1182–1186PubMedCrossRefGoogle Scholar
  9. 9.
    Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31PubMedCrossRefGoogle Scholar
  10. 10.
    Takei Y, Nemoto T, Mu P, Fujishima T, Ishimoto T, Hayakawa Y, Yuzawa Y, Matsuo S, Muramatsu T, Kadomatsu K (2008) In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency. Mol Cancer Ther 7:211–221PubMedCrossRefGoogle Scholar
  11. 11.
    Takei Y, Kadomatsu K, Goto T, Muramatsu T (2006) Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 107:864–873PubMedCrossRefGoogle Scholar
  12. 12.
    Takei Y, Kadomatsu K, Matsuo S et al (2001) Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 61:8486–8491PubMedGoogle Scholar
  13. 13.
    Takei Y, Kadomatsu K, Itoh H et al (2002) 5′-,3′-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy. J Biol Chem 277:23800–23806PubMedCrossRefGoogle Scholar
  14. 14.
    Takei Y, Kadomatsu K, Yuasa K, Sato W, Muramatsu T (2005) Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int J Cancer 114:490–497PubMedCrossRefGoogle Scholar
  15. 15.
    Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, Takei Y (2009) Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 125:2978–2990PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Yoshifumi Takei
    • 1
    • 2
  1. 1.Division of Disease Models, Center for Neurological Disease and CancerNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Department of BiochemistryNagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations